Weight Management 2 min read

Retatrutide vs. Tirzepatide vs. Semaglutide

META-TITLE: [TODO: Retatrutide vs Tirzepatide vs Semaglutide — Comparison | Brand]
META-DESC: [TODO: Side-by-side comparison of three GLP-1 pathway peptides — receptor targets, efficacy data, safety, research protocols.]

[TODO] Hook — three generations of incretin-based peptides (mono → dual → triple agonist), why researchers compare them, what this guide covers

[IMAGE: Side-by-side comparison infographic — 3 columns: Semaglutide / Tirzepatide / Retatrutide with key stats]

Quick Comparison

[TODO] Table: Receptor targets — GLP-1 only vs GLP-1+GIP vs GLP-1+GIP+GCGR
[TODO] Table: Max weight reduction in trials — ~15% vs ~22% vs ~24%
[TODO] Table: Half-life — ~7d vs ~5d vs ~6d
[TODO] Table: Developer — Novo Nordisk vs Eli Lilly vs Eli Lilly
[TODO] Table: Approval status — FDA approved vs FDA approved vs Phase 3

Semaglutide Profile

[TODO] GLP-1 mono-agonist, longest track record, most safety data
[TODO] STEP/SELECT/FLOW trials — weight, CV, renal outcomes
[TODO] Established titration protocol, well-characterized side effect profile

Tirzepatide Profile

[TODO] First dual GLP-1/GIP agonist, superior to semaglutide in SURPASS-2
[TODO] Unique GIP component — may reduce nausea vs pure GLP-1 agonists
[TODO] Broader metabolic effects — insulin sensitivity, lipid metabolism

Retatrutide Profile

[TODO] Triple agonist — adds glucagon receptor for energy expenditure
[TODO] Highest weight reduction in Phase 2 data, liver fat reduction notable
[TODO] Least clinical data — Phase 2 only, Phase 3 ongoing

Head-to-Head Research Findings

[IMAGE: Bar chart comparing weight reduction percentages across landmark trials]

[TODO] Efficacy progression — each generation shows numerically greater weight reduction
[TODO] Cross-trial comparison caveats — different populations, durations, titration schedules
[TODO] GI tolerability — triple agonist does not appear significantly worse
[TODO] Metabolic markers — liver fat, lipids, HbA1c across all three